Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APRE NASDAQ:BFRI NASDAQ:GLMD NASDAQ:SNGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPREAprea Therapeutics$1.55+3.3%$1.70$1.41▼$5.01$9.03M1.332,002 shs19,812 shsBFRIBiofrontera$0.84+0.6%$0.90$0.54▼$2.22$8.56M0.49344,053 shs77,510 shsGLMDGalmed Pharmaceuticals$1.36+6.3%$1.66$1.15▼$23.80$2.25M0.56215,738 shs62,059 shsSNGXSoligenix$2.86-5.9%$2.28$1.09▼$6.23$12.26M2.0510.20 million shs234,049 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPREAprea Therapeutics+3.33%-0.96%-5.49%-11.43%-55.71%BFRIBiofrontera+0.64%-4.72%-17.23%+40.72%-25.94%GLMDGalmed Pharmaceuticals+6.25%+7.09%-6.21%-9.93%-51.60%SNGXSoligenix-5.92%-7.74%-10.63%+48.19%-29.73%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPREAprea Therapeutics$1.55+3.3%$1.70$1.41▼$5.01$9.03M1.332,002 shs19,812 shsBFRIBiofrontera$0.84+0.6%$0.90$0.54▼$2.22$8.56M0.49344,053 shs77,510 shsGLMDGalmed Pharmaceuticals$1.36+6.3%$1.66$1.15▼$23.80$2.25M0.56215,738 shs62,059 shsSNGXSoligenix$2.86-5.9%$2.28$1.09▼$6.23$12.26M2.0510.20 million shs234,049 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPREAprea Therapeutics+3.33%-0.96%-5.49%-11.43%-55.71%BFRIBiofrontera+0.64%-4.72%-17.23%+40.72%-25.94%GLMDGalmed Pharmaceuticals+6.25%+7.09%-6.21%-9.93%-51.60%SNGXSoligenix-5.92%-7.74%-10.63%+48.19%-29.73%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPREAprea Therapeutics 3.00Buy$15.50900.00% UpsideBFRIBiofrontera 3.00Buy$2.75225.71% UpsideGLMDGalmed Pharmaceuticals 2.00HoldN/AN/ASNGXSoligenix 3.00Buy$6.00109.79% UpsideCurrent Analyst Ratings BreakdownLatest GLMD, BFRI, SNGX, and APRE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/16/2025SNGXSoligenixAlliance Global PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$10.00 ➝ $6.006/26/2025APREAprea TherapeuticsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$11.00(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPREAprea Therapeutics$1.50M6.02N/AN/A$3.55 per share0.44BFRIBiofrontera$37.32M0.23N/AN/A$0.57 per share1.48GLMDGalmed PharmaceuticalsN/AN/AN/AN/A$9.87 per shareN/ASNGXSoligenix$120K102.25N/AN/A$1.64 per share1.74Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPREAprea Therapeutics-$12.96M-$2.32N/AN/AN/A-1,645.01%-78.90%-62.67%11/6/2025 (Estimated)BFRIBiofrontera-$17.76M-$2.26N/AN/AN/A-42.34%-1,104.09%-82.28%11/12/2025 (Estimated)GLMDGalmed Pharmaceuticals-$7.52M-$16.66N/A∞N/AN/A-20.69%-18.41%11/12/2025 (Estimated)SNGXSoligenix-$8.27M-$3.80N/AN/AN/AN/A-274.76%-129.20%11/14/2025 (Estimated)Latest GLMD, BFRI, SNGX, and APRE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025SNGXSoligenix-$0.79-$0.82-$0.03-$0.82N/AN/A8/13/2025Q2 2025BFRIBiofrontera-$0.45-$0.57-$0.12-$0.57$8.30 million$9.03 million8/12/2025Q2 2025APREAprea Therapeutics-$0.77-$0.53+$0.24-$0.53N/A$0.12 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPREAprea TherapeuticsN/AN/AN/AN/AN/ABFRIBiofronteraN/AN/AN/AN/AN/AGLMDGalmed PharmaceuticalsN/AN/AN/AN/AN/ASNGXSoligenixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPREAprea TherapeuticsN/A5.345.34BFRIBiofrontera8.990.960.75GLMDGalmed PharmaceuticalsN/A8.718.71SNGXSoligenixN/A1.471.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPREAprea Therapeutics34.19%BFRIBiofrontera10.08%GLMDGalmed Pharmaceuticals76.14%SNGXSoligenix3.60%Insider OwnershipCompanyInsider OwnershipAPREAprea Therapeutics13.63%BFRIBiofrontera4.80%GLMDGalmed Pharmaceuticals19.80%SNGXSoligenix3.05%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPREAprea Therapeutics75.83 million5.03 millionNo DataBFRIBiofrontera7010.14 million9.65 millionNo DataGLMDGalmed Pharmaceuticals201.65 million1.33 millionNot OptionableSNGXSoligenix204.29 million4.16 millionNot OptionableGLMD, BFRI, SNGX, and APRE HeadlinesRecent News About These CompaniesSoligenix Tumbles After Company Publishes PaperSeptember 4 at 4:18 PM | baystreet.caSoligenix Announces Publication Describing Long-Term High Temperature Stability of Protein Subunit Vaccines for Ebola and Related VirusesSeptember 4 at 7:30 AM | prnewswire.comSoligenix Invited to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 2, 2025 | prnewswire.comSoligenix (NASDAQ:SNGX) Share Price Passes Above Two Hundred Day Moving Average - Should You Sell?September 2, 2025 | americanbankingnews.comSoligenix Inc. Reports Q2 2025 Earnings LossAugust 22, 2025 | msn.comCompanies Like Soligenix (NASDAQ:SNGX) Could Be Quite RiskyAugust 21, 2025 | finance.yahoo.comWhy Is Soligenix Stock Soaring On Monday?August 18, 2025 | benzinga.comSoligenix’s dusquetide granted Orphan Drug Designation in Behcet’s DiseaseAugust 18, 2025 | msn.comSoligenix Shares Surge After FDA Grants Orphan Drug StatusAugust 18, 2025 | msn.comSoligenix stock soars after FDA grants orphan drug designationAugust 18, 2025 | za.investing.comFDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study ResultsAugust 18, 2025 | prnewswire.comSoligenix Faces Nasdaq Non-Compliance NoticeAugust 16, 2025 | msn.comSOLIGENIX, INC.: Soligenix Announces Recent Accomplishments And Second Quarter 2025 Financial ResultsAugust 14, 2025 | finanznachrichten.deSoligenix receives FDA orphan designation for dusquetideAugust 14, 2025 | msn.comSoligenix Announces Recent Accomplishments And Second Quarter 2025 Financial ResultsAugust 14, 2025 | prnewswire.comSoligenix Inc. (NASDAQ: SNGX) Proprietary Platform Aims to Meet Growing Need for Effective CTCL TherapyAugust 8, 2025 | finance.yahoo.comNetworkNewsAudio Announces Audio Press Release (APR) on Promising First-Line Therapy for Rare Skin CancerAugust 8, 2025 | globenewswire.comSoligenix Inc. (NASDAQ: SNGX) Proprietary Platform Aims to Meet Growing Need for Effective CTCL ...August 7, 2025 | gurufocus.comSoligenix Inc. (NASDAQ: SNGX) Proprietary Platform Aims to Meet Growing Need for Effective CTCL ...August 7, 2025 | gurufocus.comSoligenix Completes Phase 2a Study for SGX945August 6, 2025 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGLMD, BFRI, SNGX, and APRE Company DescriptionsAprea Therapeutics NASDAQ:APRE$1.55 +0.05 (+3.33%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$1.55 0.00 (0.00%) As of 09/5/2025 05:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.Biofrontera NASDAQ:BFRI$0.84 +0.01 (+0.64%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$0.83 -0.02 (-1.81%) As of 09/5/2025 06:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.Galmed Pharmaceuticals NASDAQ:GLMD$1.36 +0.08 (+6.25%) Closing price 09/5/2025 03:59 PM EasternExtended Trading$1.36 0.00 (0.00%) As of 09/5/2025 06:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.Soligenix NASDAQ:SNGX$2.86 -0.18 (-5.92%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$2.86 +0.01 (+0.17%) As of 09/5/2025 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
